Outcomes and risk management in type B aortic dissection patients with acute kidney injury: a concise review

PurposeType B aortic dissection is a rare but life-threatening disease. Thoracic endovascular aortic repair (TEVAR) was widely used for Type B aortic dissection patients in the last decade due to the lower mortality and morbidity compared with open chest surgical repair (OCSR). AKI in type B aortic dissection is a well-recognized complication and indicates poor short-term and long-term outcome. The objective of this concise review was to identify the risk factors and the impact of AKI on type B aortic dissection patients.Methods and resultsA literature search was performed using PubMed, Embase, MEDLINE, and Cochrane Library with the search terms ‘type B aortic dissection’ and ‘acute kidney injury’ (AKI), and all English-language literatures published in print or available online from inception through August 2020 were thoroughly reviewed. Studies that reported relative AKI risks and outcomes in type B aortic dissection patient were included. Major mechanisms of AKI in type B aortic dissection included renal hypoperfusion, inflammation response, and the use of contrast medium. Type B aortic dissection patients with AKI significantly had increased hospital stay duration, need of renal replacement therapy, and 30-d and 1-year mortality.ConclusionsAKI in type B aortic dissection is a well-recognized complication and associated with poor short-term and long-term outcome. Early identification of high-risk patients, early diagnosis of AKI, stabilization of the hemodynamic parameters, avoidance of nephrotoxic drugs, and optimization of the use of contrast agents are the major strategies for the reduction of AKI in type B aortic dissection patients.     

COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments

Clinical Rheumatology - Since December 2019, the pandemic caused by coronavirus disease 2019 (COVID-19) raises a real public health problem. COVID-19 appeared in Wuhan (Hubei province) in China....     

不同病理类型原发性甲状旁腺功能亢进症临床表现的比较分析

目的 分析不同病理类型甲状旁腺功能亢进（PHPT）的临床表现特点。方法 回顾性分析1958-2005年北京协和医院收治经手术病理证实的280例PHPT患者的临床资料。按病理类型分为甲状旁腺腺瘤组208例，甲状旁腺增生组52例及甲状旁腺腺癌组20例。结果 腺癌组中男性高于另外2组（P〈0．05）。增生及腺癌组中骨畸形、骨软化比例较低，增生组骨吸收、病理性骨折比例低于腺瘤组；胃肠道症状、多饮多尿及泌尿系统病变在腺癌组中高于另外2组（P均〈0．05）。血总钙（TCa）、血游离钙离子（ICa）及24h尿Ca在腺癌组显著高于腺瘤组及增生组（P均〈0．01），在腺瘤组与增生组间差异无统计学意义（P〉0．05）。出现高钙危象的比例在腺癌组显著高于另外2组（P〈0．01）。腺癌组病灶重量高于增生组，腺瘤组病灶直径小于增生组（P均〈0．05）。结论 在本组病例中，腺癌组男性比例较高，泌尿系统病变更为多见，出现高钙危象的比例显著增高，术后复发的比例较高。增生组骨骼系统病变相对较轻，其病变甲状旁腺重量低于腺癌与腺瘤组。     

人工生物材料和医疗器具的安全性与可靠性

本文重点论述人工生物材料的可靠性、安全性及其保证措施。     

硬膜外镇痛分娩法的临床观察

随着医学科学的发展,人们生活水平的提高，人们一直在寻找一种安全有效的分娩镇痛方法，以减轻分娩的痛苦。我科自2005年开展硬膜外镇痛术，取得了良好的效果，现报告如下。     

Bilirubin and the laboratory. Advances in the 1980s, considerations for the 1990s

The limitations of current methods of measuring bilirubin are well established and relate to the broad dynamic range and inability of the technique to determine different but structurally similar bilirubin species. New instrumentation and methodology circumvent these limitations, and clinical studies are beginning to reveal their increased diagnostic usefulness. Nevertheless, in several clinical situations, for example, the prediction of kernicterus, better bilirubin determinations may not eliminate the controversy surrounding appropriate therapeutic interventions.     

国外护理人力资源配置研究方法介绍

对国外护理人力资源配置研究常用的方法进行介绍，包括3个方面，分别是患者依赖性分类法、疾病严重程度分类法和护理强度测定方法，旨在为我国护理人力资源配置研究人员提供参考。     

Partial purification and osteoinductive activity of swine bone morphogenetic protein.

Bone morphogenetic protein (BMP) was isolated from the bone matrix of swine and partially purified by means of differential precipitation and molecular sieve chromatography. The molecular weight of BMP estimated by SDS-gel electrophoresis was 19,000 dalton. Bioassay by implanting two milligrams of BMP fraction into thigh muscles of mice resulted in bone formation in 100% of the experimental animals.

     

地尔硫卓联合地高辛治疗心力衰竭并慢性快速房颤分析

目的观察地尔硫卓联合小剂量地高辛对心力衰竭并慢性快速房颤患者血压、心室率和心功能的影响。方法 :心功能Ⅱ～Ⅲ级慢性房颤患者 10 6例 ,随机分为二组 ,对照组 5 0例 ,单用地高辛 ,治疗组 5 6例 ,地尔硫卓与地高辛联用 ,其余治疗二组相同 ,7～ 10d为一疗程 ,观察治疗前后血压、心率、左室射血分数 (LVEF)、心输出量 (CO)。结果 :治疗组较对照组心室率明显下降 ,控制满意 ,血压、LVEF及CO变化二组相似。结论 :地尔硫卓联合小剂量地高辛治疗心衰并慢性快速房颤患者心室率较单用地高辛效果更好 ,且较为安全。